In 2001 metformin appeared on the cancer scene when it was observed that in hepatocytes it stimulated the AMP-activated serine threonine protein kinase (AMPK) (2), a sensor of the energetic cellular status and an important tumor suppressor pathway (3, 4). Here, PRKAA2 is linked to neoplasm.